Inhibitor Development in a Multitransfused Patient with Severe Haemophilia A

Thromb Haemost 1999; 82(01): 151-152
DOI: 10.1055/s-0037-1614648

Letters to the Editor

Schattauer GmbH

H. M. van den Berg

¹From the Van Creveld Clinic, University Hospital Utrecht/Wilhelmina Childrens’ Hospital, Utrecht, The Netherlands

,

G. Roosendaal

¹From the Van Creveld Clinic, University Hospital Utrecht/Wilhelmina Childrens’ Hospital, Utrecht, The Netherlands

,

J. Voorberg

²From the CLB Sanquin Blood Supply Foundation, The Netherlands

,

E.P. Mauser-Bunschoten

¹From the Van Creveld Clinic, University Hospital Utrecht/Wilhelmina Childrens’ Hospital, Utrecht, The Netherlands

References
1 McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao V, Lazerson J. and the Hemophilia Study group. The natural history of factor VIII:C inhibitors in patients with hemophilia: A national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood 1988; 71: 344-8.
2 Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, Van den Berg HM. Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood 1995; 86: 983-8.
3 Rosendaal FR, Nieuwenhuis HK, van den Berg HM. et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Blood 1993; 81: 2180-6.
4 Peerlinck K, Arnout J, Di Giambattista M. et al. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate. Thromb Haemost 1997; 77: 80-6.
5 Sawamoto Y, Prescott R, Zhong D. et al. Dominant C2 domain epitope specificity of inhibitor antibodies elicited by a heat pasteurized product, factor VIII CPS-P, in previously treated hemophilia A patients without inhibitors. Tromb Haemost 1998; 79: 62-8.